Persistent bacterial infections: The interface of the pathogen and the host immune system

Nature Reviews Microbiology

Volumn 2, Issue 9, 2004, Pages 747-765

  Monack, Denise M ^a   Mueller, Anne ^a   Falkow, Stanley ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CLEARANCE; DISEASE ASSOCIATION; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHI; SEROTYPE; TISSUE INJURY;

BACTERIA; BACTERIAL INFECTIONS; CHRONIC DISEASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; TUBERCULOSIS; TYPHOID FEVER;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; SALMONELLA; SALMONELLA ENTERICA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SALMONELLA TYPHI;

EID: 4444349432     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro955     Document Type: Review

References (249)

1. Young, D., Hussell, T. & Dougan, G. Chronic bacterial infections: living with unwanted guests. Nature Immunol. 3, 1026-1032 (2002).
2. Rhen, M., Eriksson, S., Clements, M., Bergstrom, S. & Normark, S. J. The basis of persistent bacterial infections. Trends Microbiol. 11, 80-86 (2003).
3. Everhart, J. E. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol. Clin. North Am. 29, 559-578 (2000).
4. Kaufmann, S. H. How can immunology contribute to the control of tuberculosis? Nature Rev. Immunol. 1, 20-30 (2001).
5. Stewart, G. R., Robertson, B. D. & Young, D. B. Tuberculosis: a problem with persistence, Nature Rev. Microbiol. 1, 97-105 (2003).
6. Peek, R. M. & Blaser, M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev. Cancer 2, 28-37 (2002).
7. Shukla, V. K., Singh, H., Pandey, M., Upadhyay, S. K. & Nath, G. Carcinoma of the gallbladder - is it a sequel of typhoid? Dig. Dis. Sci. 45, 900-903 (2000).
8. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686 (1999).
9. Geijtenbeek, T. B. et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197, 7-17 (2003).
10. Tailleux, L. et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197, 121-127 (2003).
11. Balasubramanian, V., Wiegeshaus, E. H., Taylor, B. T. & Smith, D. W. Pathogenesis of tuberculosis: pathway to apical localization. Tuber. Lung Dis. 75, 168-178 (1994).
12. Gedde-Dahl, T. Tuberculous infection in the light of tuberculin matriculation. Am. J. Hyg. 56, 139-214 (1952).
13. Park, D. R. et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J. Infect. Dis. 184, 268-277 (2001).
14. Kulaga, S. et al. Molecular epidemiology of tuberculosis in Montreal. CMAJ 167, 353-354 (2002).
15. Adams, D. O. The granulomatous inflammatory response. A review. Am. J. Pathol. 84, 164-191 (1976).
16. Flynn, J. L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129 (2001).
17. Peters, W. & Ernst, J. D. Mechanisms of cell recruitment in the immune response to Mycobacterium tuberculosis. Microbes Infect. 5, 151-158 (2003).
18. Roach, D. R., Briscoe, H., Baumgart, K., Rathjen, D. A. & Britton, W. J. Tumor necrosis factor (TNF) and a TNF-mimetic peptide modulate the granulomatous response to Mycobacterium bovis BCG infection in vivo. Infect. Immun. 67, 5473-5476 (1999).
19. Parrish, N. M., Dick, J. D. & Bishi W. R. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6, 107-112 (1998).
20. Manabe, Y. C. & Bishai W. R. Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nature Med. 6, 1327-1329 (2000).
21. McKinney, J. D. In vivo veritas: the search for TB drug targets goes live. Nature Med. 6, 1330-1333 (2000).
22. Cosma, C. L., Sherman, D. R. & Ramakrishnan, L. The secret lives of the pathogenic mycobacteria. Annu. Rev. Microbiol. 57, 641-676 (2003).
23. Russell, D. G. Mycobacterium tuberculosis: here today, and here tomorrow. Nature Rev. Mol. Cell Biol. 2, 569-577 (2001).
24. Koul, A., Hargett, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nature Rev. Microbiol. 2, 189-202 (2004).
25. Bouley, D. M., Ghori, N., Mercer, K. L., Falkow, S. & Ramakrishnan, L. Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas. Infect. Immun. 69, 7820-7831 (2001).
26. Timm, J. et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc. Natl Acad. Sci. USA 100, 14321-14326 (2003).
27. H1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc. Natl Acad. Sci. USA 100, 241-246 (2003).
28. Schnappinger, D. et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198, 693-704 (2003).
29. Voskuil, M. I. et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705-713 (2003).
30. Talaat, A. M., Lyons, R., Howard, S. T. & Johnston, S. A. The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc. Natl Acad. Sci. USA 101, 4602-4607 (2004).
31. Ramakrishnan, L., Federspiel, N. A. & Falkow, S. Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 288, 1436-1439 (2000).
32. Verreck, F. A. et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl Acad. Sci. USA 101, 4560-4565 (2004).
33. Casanova, J. L. & Abel, L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581-620 (2002).
34. Chan, J., Xing, Y., Magliozzo, R. S. & Bloom, B. R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175, 1111-1122 (1992).
35. MacMicking, J. D. et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94, 5243-5248 (1997).
36. Ehrt, S. et al. Reprogramming of the macrophage transcriptome in response to interferon-γ and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194, 1123-1140 (2001).
37. MacMicking, J. D., Taylor, G. A. & McKinney, J. D. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 302, 654-659 (2003).
38. Ting, L. M., Kim, A. C., Cattamanchi, A. & Ernst, J. D. Mycobacterium, tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163, 3898-3906 (1999).
39. Giacomini, E. et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T-cell response. J. Immunol. 166, 7033-7041 (2001).
40. Nau, G. J. et al. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl Acad. Sci. USA 99, 1503-1508 (2002).
41. Stanley, S. A., Raghavan, S., Hwang, W. W. & Cox, J. S. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc. Natl Acad. Sci. USA 100, 13001-13006 (2003).
42. Gao, L. Y. et al. Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. Mol. Microbiol. 49, 1547-1563 (2003).
43. McMurray, D. N. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7, 135-137 (2001).
44. Walsh, G. P. et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nature Med. 2, 430-436 (1996).
45. Flynn, J. L. et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb.) 133, 116-118 (2003).
46. McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445-468 (1966).
47. Scarga, C. A. et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67, 4531-4538 (1999).
48. Orme, I. M. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. 137, 716-718 (1988).
49. Rhoades, E. R., Frank, A. A. & Orme, I. M. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung. Dis. 78, 57-66 (1997).
50. Rees, R. J. & Hart, P. D. Analysis of the host-parasite equilibrium in chronic morine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. 42, 83-88 (1961).
51. Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A. & Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731 (2002).
52. Wayne, L. G. & Sohaskey C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001).
53. Boon, C. & Dick, T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J. Bacteriol. 184, 6760-6767 (2002).
54. Dasgupta, N. et al. Characterization of a two-component system, devR-devS, of Mycobacterium tuberculosis. Tuber. Lung Dis. 80, 141-159 (2000).
55. Sherman, D. R. et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin. Proc. Natl Acad. Sci. USA 98, 7534-7539 (2001).
56. Dannenberg, A. M., Ando, M. & Shima, K. Macrophage accumulation, division, maturation, and digestive and microbicidal capacities in tuberculous lesions. 3. The turnover of macrophages and its relation to their activation and antimicrobial immunity in primary BCG lesions and those of reinfection. J. Immunol. 109, 1109-1121 (1972).
57. Chan, K. et al. Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. Proc. Natl Acad. Sci. USA 99, 3920-3925 (2002).
58. Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl Acad. Sci. USA 98, 12712-12717 (2001).
59. Sassetti, C. M. & Rubin, E. J. Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad. Sci. USA 100, 12989-12994 (2003).
60. McKinney, J. D. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
61. Zahrt, T. C. & Deretic, V. Mycobacterium tuberculosis signal transduction system required for persistent infections. Proc. Natl Acad. Sci. USA 98, 12706-12711 (2001).
62. Karakousis, P. C., Bishai, W. R. & Dorman, S. E. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell. Microbiol. 6, 105-116 (2004).
63. Glickman, M. S., Cox, J. S. & Jacobs, W. R. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000).
64. Cosma, C. L., Humbert, O. & Ramakrishnan, L. Superinfecting mycobacteria home to established tuberculous granulomas. Nature Immunol. 27 June 2004 (doi:10.1038/ni1091).
65. Caruso, A. M. et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J. Immunol. 162, 5407-5416 (1999).
66. van Pinxteren, L. A., Cassidy, J. P., Smedegaard, B. H., Agger, E. M. & Andersen, P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J. Immunol. 30, 3689-3698 (2000).
67. + T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon-γ and nitric oxide synthase 2. J. Exp. Med. 192, 347-358 (2000).
68. + CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. J. Immunol. 165, 353-363 (2000).
69. Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125 (1998).
70. Turner, J. et al. CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am. J. Respir. Cell Mol. Biol. 24, 203-209 (2001).
71. Barnes, P. F. et al. Cytolkine production at the site of disease in human tuberculosis. Infect. Immun. 61, 3482-3489 (1993).
72. Barnes, P. F. et al. Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect. Immun. 61, 197-203 (1993).
73. Verbon, A. et al. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin. Exp. Immunol. 115, 110-113 (1999).
74. Turner, J. et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169, 6343-6351(2002).
75. Flynn, J. L. et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995).
76. Turner, J., Frank, A. A., Brooks, J. V., Marietta, P. M. & Orme, I. M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102, 248-253 (2001).
77. Kindler, V., Sappino, A. P., Grau, G. E., Piguet, P. F. & Vassalli, P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56, 731-740 (1989).
78. Mohan, V. P. et al. Effects of tumor necrosis factor-α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69, 1847-1855 (2001).
79. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
80. Carter, P. B. & Collins, F. M. Peyer's patch responsiveness to Salmonella in mice. J. Reticuloendothel. Soc. 17, 38-46 (1975).
81. Vasquez-Torres, A. et al. Extraintestinal dissemination of Salmonella via CD18-expressing phagocytes. Nature 401, 804-808 (1999).
82. Sinnott, C. R. & Teall, A. J. Persistent gallbladder carriage of Salmonella typhi. Lancet 1, 976 (1987).
83. Wain, J. et al. Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J. Clin. Microbiol. 39, 1571-1576 (2001).
84. House, D., Bishop, A., Parry, C., Dougan, G. & Wain, J. Typhoid fever: pathogenesis and disease. Curr. Opin. Infect. Dis. 14, 573-578 (2001).
85. Wain, J. et al. Molecular typing of multiple-antibiotic-resistant Salmonella enterica serovar Typhi from Vietnam: application to acute and relapse cases of typhoid fever. J. Clin. Microbiol. 37, 2466-2472 (1999).
86. Ledingham, J. C. G. & Arkwright, J. A. The Carrier Problem in Infectious Disease (Edward Arnold, London, 1912).
87. Stokes, A. & Clarke, C. A search for typhoid carriers among 800 convalescents. Lancet 1, 566-569 (1912).
88. Levine, M. M., Black, R. E. & Lanata, C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J. Infect. Dis. 146, 724-726 (1982).
89. Vogelsang, T. M. & Boe, J. Temporary and chronic carriers of Salmonella typhi and Salmonella paratyphi B. Br. J. Hyg. 46, 252-261 (1948).
90. Bao, X., Qiu, J., Yang, N., Mei, L. & Chen, X. Study and preparation of Vi-PHA reagent and its application for detection of Salmonella typhi carters. Wei Sheng Wu Xue Bao 32, 289-295 (1992) (in Chinese).
91. Hormaeche, C. E., Harrington, K. A. & Joysey, H. S. Natural resistance to salmonellae in mice: control by genes within the major histocompatibility complex. J. Infect. Dis. 152, 1050-1056 (1985).
92. Vidal, S. M., Malo, D., Vogan, K., Skamene, E. & Gros, P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73, 469-485 (1993).
93. Gruenheid, S., Pinner, E., Desjardins, M. & Gros, P. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J. Exp. Med. 185, 717-730 (1997).
94. Vidal, S. et al. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J. Exp. Med. 182, 655-666 (1995).
95. Nauciel, C., Ronco, E., Guenet, J. L. & Pla, M. Role of H-2 and non-H-2 genes in control of bacterial clearance from the spleen in Salmonella typhimurium-infected mice. Infect. Immun. 56, 2407-2411 (1988).
96. Dunstan, S. J. et al. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J. Infect. Dis. 183, 261-268 (2001).
97. + T cells and T-independent mechanisms in acquired resistance to Salmonella typhimurium infection, J. Immunol. 145, 1265-1269 (1990).
98. H1 cylokine production. J. Immunol. 161, 2762-2771 (1998).
99. Mittrucker, H. W., Kohler, A., Mak, T. W. & Kaufmann, S. H. Critical role of CD28 in protective immunity against Salmonella typhimurium. J. Immunol. 163, 6769-6776 (1999).
100. Mittrucker, H. W., Raupach, B., Kohler, A. & Kaufmann, S. H. Cutting edge: role of B lymphocytes in protective immunity against Salmonella typhimurium infection. J. Immunol. 164, 1648-1652 (2000).
101. Rawlings, D. J. et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261, 358-361 (1993).
102. Thomas, J. D. et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355-358 (1993).
103. Sukupolvi, S., Edelstein, A., Rhen, M., Normark, S. J. & Pfeifer, J. D. Development of a murine model of chronic Salmonella infection. Infect. Immun. 65, 838-842 (1997).
104. Stocker, B. A. Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. J. Biotechnol. 83, 45-50 (2000).
105. Yamamoto, T. et al. Disruption of the genes for ClpXP protease in Salmonella enterica serovar Typhimurium results in persistent infection in mice, and development of persistence requires endogenous γ-interferon and tumor necrosis factor-α. Infect. Immun. 69, 3164-3174 (2001).
106. +/+ mice and can be reactivated by IFN-γ neutralization. J. Exp. Med. 199, 231-241 (2004).
107. Anderson, G. W., Hamblen, A. D. & Smith, H. M. Typhoid carriers. A study of their disease-producing potentialities over a series of years as indicated by a study of cases. Am. J. Public Health 26, 396-405 (1936).
108. Buchwald, D. S. & Blaser, M. J. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev. Infect. Dis. 6, 345-356 (1984).
109. Edelman, R. & Levine, M. M. Summary of an international workshop on typhoid fever. Rev. Infect. Dis. 8, 329-349 (1986).
110. Dinbar, A., Altmann, G. & Tulcinsky, D. B. The treatment of chronic hillary salmonella carriers. Am. J. Med. 47, 236-242 (1969).
111. Gaines, S., Sprinz, H., Tully, J. G. & Tigertt, W. D. Studies on infection and immunity in experimental typhoid fever. VII. The distribution of Salmonella typhi in chimpanzee tissue following oral challenge, and the relationship between the numbers of bacilli and morphologic lesions. J. Infect. Dis. 118, 293-306 (1968).
112. Wigley, P., Berchieri, A., Page, K. L., Smith, A. L. & Barrow, P. A. Salmonella enterica serovar Pullorum persists in splenic macrophages and in the reproductive tract during persistent, disease-free carriage in chickens. Infect. Immun. 69, 7873-7879 (2001).
113. Holden, D. W. Trafficking of the Salmonella vacuole in macrophages. Traffic 3, 161-169 (2002).
114. Eriksson, S., Lucchini, S., Thompson, A., Rhen, M. & Hinton, J. C. Unraveling the biology of macrophage infection by gene expression profiling of intracellular Salmonella enterica. Mol. Microbiol. 47, 103-118 (2003).
115. Richter-Dahlfors, A., Buchan, A. M. J. & Finlay, B. B. Murine salmonellosis studied by confocal microscopy: Salmonella typhimurium resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes in vivo. J. Exp. Med. 186, 569-580 (1997).
116. Monack, D. M. et al. Salmonella exploits caspase-1 to colonize Payer's patches in a murine typhoid model. J. Exp. Med. 192, 249-258 (2000).
117. Monack, D. M., Raupach, B., Hromockyj, A. E. & Falkow, S. Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc. Natl Acad. Sci. USA 93, 9833-9838 (1996).
118. van Der Velden, A. W., Lindgren, S. W., Worley, M. J. & Heffron, F. Salmonella pathogenicity island 1-independent induction of apoptosis in infected macrophages by Salmonella enterica serotype Typhimurium. Infect. Immun. 68, 5702-5709 (2000).
119. Monack, D. M., Detweiler, C. S. & Falkow, S. Salmonella pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1. Cell. Microbiol. (2001).
120. Clements, M. O. et al. Polynucleotide phosphorylase is a global regulator of virulence and persistency in Salmonella enterica. Proc. Natl Acad. Sci. USA 99, 8784-8789 (2002).
121. Vazquez-Torres, A. et al. Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. Science 287, 1655-1658 (2000).
122. Hensel, M. Salmonella pathogenicity island 2. Mol. Microbiol. 36, 1015-1023 (2000).
123. Wigley, P., Jones, M. A. & Barrow, P. A. Salmonella enterica serovar Pullorum requires the Salmonella pathogenicity island 2 type III secretion system for virulence and carriage in the chicken. Avian Pathol. 31, 501-506 (2002).
124. Salcedo, S. P., Noursadeghi, M., Cohen, J. & Holden, D. W. Intracellular replication of Salmonella typhimurium strains in specific subsets of splenic macrophages in vivo. Cell. Microbiol. 3, 587-597 (2001).
125. Nauciel, C. & Espinasse-Maes, F. Role of γ-interferon and tumor necrosis factor-α in resistance to Salmonella typhimurium infection. Infect. Immun. 60, 450-454 (1992).
126. Pie, S., Matsiota-Bernard, P., Truffa-Bachi, P. & Nauciel, C. γ-interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of Salmonella typhimurium infection. Infect. Immun. 64, 849-854 (1996).
127. Mastroeni, P. et al. Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of γ-interferon and macrophage activation. Infect. Immun. 66, 4767-4776 (1998).
128. Jouanguy, E. et al. IL-12 and IFN-γ in host defense against mycobacteria and salmonella in mice and men. Curr. Opin. Immunol. 11, 346-351 (1999).
129. Netea, M. G. et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-γ production and Toll-like receptor 4 expression. Arthritis Rheum. 48, 1853-1857 (2003).
130. Mittrucker, H. W., Kohler, A. & Kaufmann, S. H. Characterization of the murine T-lymphocyte response to Salmonella enterica serovar Typhimurium infection. Infect. Immun. 70, 199-203 (2002).
131. Eisenstein, T. K., Huang, D., Meissler, J. J. & al-Ramadi, B. Macrophage nitric oxide mediates immunosuppression in infectious inflammation. Immunobiology 191, 493-502 (1994).
132. H1 response in Salmonella typhimurium-infected mice with a high or low rate of bacterial clearance. Infect. Immun. 65, 4509-4514 (1997).
133. MacFarlane, A. S., Schwacha, M. G. & Eisenstein, T. K. In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen. Infect. Immun. 67, 891-898 (1999).
134. Valdivia, R. H., Cirillo, D. M., Lee, A. K., Bouley, D. M. & Falkow, S. mig-14 is a horizontally acquired, host-induced gene required for Salmonella enterica lethal infection in the murine model of typhoid fever. Infect. Immun. 68, 7126-7131 (2000).
135. Detweiler, C. S., Monack, D. M., Brodsky, I. E., Mathew, H. & Falkow, S. virK, somA and rcsC are important for systemic Salmonella enterica serovar Typhimurium infection and cationic peptide resistance. Mol. Microbiol. 48, 385-400 (2003).
136. Rosenberger, C. M., Gallo, R. L. & Finlay, B. B. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl Acad. Sci. USA 101, 2422-2427 (2004).
137. Nomura, A., Stemmermann, G. N., Chyou, P. H., Perez-Perez. G. I. & Blaser, M. J. Helicobacter pylori infection and the risk for duodenal and gastric ulceration, Ann. Intern. Med. 120, 977-981 (1994).
138. Marshall, B. Helicobacter pylori: 20 years on. Clin. Med. 2, 147-152 (2002).
139. Montecucco, C. & Rappuoli, R. Living dangerously: how Helicobacter pylori survives in the human stomach. Nature Rev. Mol. Cell Biol. 2, 457-466 (2001).
140. Karnes, W. E. et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 101, 167-174 (1991).
141. O'Rourke, J. L. & Lee, A. Animal models of Helicobacter pylori infection and disease. Microbes Infect. 5, 741-748 (2003).
142. Hoffman, P. S. et al. Development of an interleukin-12-deficient mouse model that is permissive for colonization by a motile KE26695 strain of Helicobacter pylori. Infect. Immun. 71, 2534-2541 (2003).
143. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl Acad. Sci. USA 97, 8841-8848 (2000).
144. Wilson, K. T. et al. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology 111, 1524-1533 (1996).
145. Fu, S. et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116, 1319-1329 (1999).
146. Gobert, A. P. et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc. Natl Acad. Sci. USA 98, 13844-13849 (2001).
147. McGee, D. J., Radcliff, F. J., Mendz, G. L., Ferrero, R. L. & Mobley, H. L. Helicobacter pylori rocF is required for arginase activity and acid protection in vitro but is not essential for colonization of mice or for urease activity. J. Bacteriol 181, 7314-7322 (1999).
148. Allen, L. A., Schlesinger, L. S. & Kang, B. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. J. Exp. Med. 191, 115-128 (2000).
149. Ramarao, N., Gray-Owen, S. D., Backert, S. & Meyer, T. F. Helicobacter pylori inhibits phagocytosis by professional phagocytes involving type IV secretion components. Mol. Microbiol. 37, 1389-1404 (2000).
150. Ramarao, N. & Meyer, T. F. Helicobacter pylori resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence-activated cell sorting. Infect. Immun. 69, 2604-2611 (2001).
151. Parsonnet, J., Friedman, G. D., Orentreich, N. & Vogelman, H. Risk for gastric cancer in people with CagA-positive or CagA-negative Helicabacter pylori infection. Gut 40, 297-301 (1997).
152. Perez-Perez, G. I., Peek, R. M., Legath, A. J., Heine, P. R. & Graff, L. B. The role of CagA status in gastric and extragastric complications of Helicobacter pylori. J. Physiol. Pharmacol. 50, 833-845 (1999).
153. Webb, P. M., Crabtree, J. E. & Forman, D. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study. The Eurogst Study Group. Gastroenterology 116, 269-276 (1999).
154. Ermak, T. H. et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188, 2277-2288 (1998).
155. Knipp, U., Birkholz, S., Kaup, W., Mahnke, K. & Opferkuch, W. Suppression of human mononuclear cell response by Helicobacter pylori: effects on isolated monocytes and lymphocytes. FEMS Immunol. Med. Microbiol. 8, 157-166 (1994).
156. Gebert, B., Fischer, W., Weiss, E., Hoffmann, R. & Haas, R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301, 1099-1102 (2003).
157. Boncristiano, M. et al. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J. Exp. Med. 198, 1887-1897 (2003).
158. Cover, T. L. & Blaser, M. J. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J. Biol. Chem. 267, 10570-10575 (1992).
159. Montecucco, C., De Bernard, M., Papini, E. & Zoratti, M. Helicobacter pylori vacuolating cytotoxin: cell intoxication and anion-specific channel activity. Curr. Top. Microbiol. Immunol. 257, 113-129 (2001).
160. Molinari, M. et al. Selective inhibition of li-dependent antigen presentation by Helicobacter pylori toxin VacA. J. Exp. Med. 187, 135-140 (1998).
161. Molinari, M. et al. Vacuoles induced by Helicobacter pylori toxin contain both late endosomal and lysosomal markers. J. Biol Chem 272, 25339-25344 (1997).
162. Ricci, V. et al. Helicobacter pylori vacuolating toxin accumulates within the endosomal-vacuolar compartment of cultured gastric cells and potentiates the vacuolating activity of ammonia. J. Pathol. 183, 453-459 (1997).
163. Salama, N. R., Otto, G., Tompkins, L. & Falkow, S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect. Immun. 69, 730-736 (2001).
164. Blaser, M. J. & Parsonnet, J. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest 94, 4-8 (1994).
165. Perez-Perez, G. I., Shepherd, V. L., Morrow, J. D. & Blaser, M. J. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect. Immun. 63, 1183-1187 (1995).
166. Ismail, H. F., Zhang, J., Lynch, R. G., Wang, Y. & Berg, D. J. Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice. Infect. Immun. 71, 7140-7148 (2003).
167. Blanchard, T. G., Yu, F., Hsieh, C. L. & Redline, R. W. Severe inflammation and reduced bacteria load in murine helicobacter infection caused by lack of phagocyte oxidase activity. J. Infect. Dis. 187, 1609-1615 (2003).
168. Kawahara, T. et al. Type I Helicobacter pylori lipopolysacchande stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells, Infect. Immun. 69, 4382-4389 (2001).
169. Smith, M. F. et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. J. Biol. Chem. 278, 32552-32560 (2003).
170. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
171. Lee, S. K. et al. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect. 5, 1345-1356 (2003).
172. Philpott, D. J. et al. Reduced activation of inflammatory responses in host cells by mouse-adapted Helicobacter pylori isolates. Cell. Microbiol. 4, 285-296 (2002).
173. Yamaoka, Y. et al. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 41, 442-451 (1997).
174. Atherton, J. C., Tham, K. T., Peek, R. M., Cover, T. L. & Blaser, M. J. Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology. J. Infect. Dis. 174, 552-556 (1996).
175. Kersulyte, D., Chalkauskas, H. & Berg, D. E. Emergence of recombinant strains of Helicobacter pylori during human infection. Mol. Microbiol. 31, 31-43 (1999).
176. Akopyanz, N., Bukanov, N. O., Westblom, T. U. & Berg, D. E. PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen Helicobacter pylori. Nucleic Acids Res. 20, 6221-6225 (1992).
177. Achtman, M. et al. Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol. Microbiol. 32, 459-470 (1999).
178. van Doorn, N. E. et al. Genomic DNA fingerprinting of clinical isolates of Helicobacter pylori by REP-PCR and restriction fragment end-labelling. FEMS Microbiol. Lett. 160, 145-150 (1998).
179. Suerbaum, S. et al. Free recombination within Helicobacter pylori. Proc. Natl Acad. Sci. USA 95, 12619-12624 (1998).
180. Blaser, M, J. Ecology of Helicobacter pylori in the human stomach. J. Clin. Invest. 100, 759-762 (1997).
181. Blaser, M. J. & Berg, D. E. Helicobacter pylori genetic diversity and risk of human disease. J. Clin. Invest. 107, 767-773 (2001).
182. Covacci, A. & Rappuoli, R. Helicobacter pylori: molecular evolution of a bacterial quasi-species. Curr. Opin. Microbiol. 1, 96-102 (1998).
183. Israel, D. A. et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc. Natl Acad. Sci. USA 98, 14625-14630 (2001).
184. Salama, N. et al. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc. Natl Acad. Sci. USA 97, 14668-14673 (2000).
185. Szpirer, C. Y., Faelen, M. & Couturier, M. Interaction between the RP4 coupling protein TraG and the pBHR1 mobilization protein Mob. Mol. Microbiol. 37, 1283-1292 (2000).
186. Cabezon, E., Sastre, J. I. & de la Cruz, F. Genetic evidence of a coupling role for the TraG protein family in bacterial conjugation. Mol. Gen. Genet. 254, 400-406 (1997).
187. Solnick, J. V., Hansen, L. M., Salama, N. R., Boonjakuakul, J. K. & Syvanen, M. Modification of Helicobacter pylori outer membrane protein expression during experimental infection of rhesus macaques. Proc. Natl Acad. Sci. USA 101, 2106-2111 (2004).
188. Ilver, D. et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279, 373-377 (1998).
189. Wang, G., Ge, Z., Rasko, D. A. & Taylor, D. E. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol. Microbiol. 36, 1187-1196 (2000).
190. Appelmelk, B. J., Monteiro, M. A., Martin, S. L., Moran, A. P. & Vandenbroucke-Grauls, C. M. Why Helicobacter pylori has Lewis antigens. Trends Microbiol. 8, 565-570 (2000).
191. Osaki, T. et al. Establishment and characterisation of a monoclonal antibody to inhibit adhesion of Helicobacter pylori to gastric epithelial cells. J. Med. Microbiol. 47, 505-512 (1998).
192. Edwards, N. J. et al. Lewis X structures in the O antigen side-chain promote adhesion of Helicobacter pylori to the gastric epithelium. Mol. Microbiol. 35, 1530-1539 (2000).
193. Hofreuter, D., Odenbreit, S. & Haas, R. Natural transformation competence in Helicabacter pylori is mediated by the basic components of a type IV secretion system. Mol. Microbiol. 41, 379-391 (2001).
194. Hofreuter, D., Odenbreit, S., Henke, G. & Haas, R. Natural competence for DNA transformation in Helicobacter pylori: identification and genetic characterization of the comB locus. Mol. Microbiol. 28, 1027-1038 (1998).
195. Kersulyte, D. et al. Cluster of type IV secretion genes in Helicobacter pylori's plasticity zone. J. Bacteriol. 185, 3764-3772 (2003).
196. Penfold, S. S., Lastovica, A. J. & Elisha, B. G. Demonstration of plasmids in Campylobacter pylori. J. Infect. Dis. 157, 850-851 (1988).
197. Hofreuter, D. & Haas, R. Characterization of two cryptic Helicobacter pylori plasmids: a putative source for horizontal gene transfer and gene shuffling. J. Bacteriol. 184, 2755-2766 (2002).
198. Kwok, T., Backert, S., Schwarz, H., Berger, J. & Meyer, T. F. Specific entry of Helicobacter pylori into cultured gastric epithelial cells via a zipper-like mechanism. Infect. Immun. 70, 2108-2120 (2002).
199. Amieva, M. R., Salama, N. R., Tompkins, L. S. & Falkow, S. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell. Microbiol. 4, 677-690 (2002).
200. Kazi, J. L. et al. Ultrastructural study of Helicobacter pylori-associated gastritis. J. Pathol 161, 65-70 (1990).
201. Bode, G., Malfertheiner, P. & Ditschuneit, H. Pathogenetic implications of ultrastructural findings in Campylobacter pylori related gastroduodenal disease. Scand. J. Gastroenterol. 142, S25-S39 (1988).
202. Foliguet, B., Vicari, F., Guedenet, J. C., De Korwin, J. D. & Marchal, L. Scanning electron microscopic study of Campylobacter pylori and associated gastroduodenal lesions. Gastroenterol. Clin. Biol. 13, 65B-70B (1989).
203. Parsonnet, J. What is the Helicobacter pylori global reinfection rate? Can. J. Gastroenterol. 17, 46B-48B (2003).
204. Hughes, E. A. & Galan, J. E. Immune response to Salmonella: location, location, location? Immunity 16, 325-328 (2002).
205. O'Callaghan, D. et al. A homologue of the Agrobacterium tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is essential for intracellular survival of Brucella suis. Mol. Microbiol. 33, 1210-1220 (1999).
206. Boschiroli, M. L. et al. The Brucella suis virB operon is induced intracellularly in macrophages. Proc. Natl Acad. Sci. USA 99, 1544-1549 (2002).
207. Byrne, G. I. et al. Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. Infect. Immun. 69, 5423-5429 (2001).
208. Fischer, S. F., Schwarz, C., Vier, J. & Hacker, G. Characterization of antiapoptotic, activities of Chlamydia pneumoniae in human cells. Infect. Immun. 69, 7121-7129 (2001).
209. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
210. Prud'homme, G. J. & Piccirillo, C. A. The inhibitory effects of transforming growth factor-β-1 (TGF-β1) in autoimmune diseases. J. Autoimmun. 14, 23-42 (2000).
211. Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
212. + T cell clones producing both interferon-γ and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin. Immunol. 92, 224-234 (1999).
213. Nishikawa, F., Yoshikawa, S., Harada, H., Kita, M. & Kita, E. The full expression of the ity phenotype in ityr mice requires C3 activation by Salmonella lipopolysaccharide. Immunology 95, 640-647 (1998).
214. + regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin. Exp. Immunol. 132, 393-400 (2003).
215. high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect. Immun. 71, 1755-1762 (2003 ).
216. Saez-Llorens, X. & McCracken, G. H. Bacterial meningitis in children. Lancet 361, 2139-2148 (2003).
217. Salyers, A. & Whitt, D. Bacterial Pathogensis - A Molecular Approach (American Society for Microbiology, Washington, DC, 1994).
218. Park, H. S., Francis, K. P., Yu, J. & Cleary, P. P. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J. Immunol. 171, 2532-2537 (2003).
219. Lengeling, A., Pfeffer, K. & Balling, R. The battle of two genomes: genetics of bacterial host/pathogen interactions in mice. Mamm. Genome 12, 261-271 (2001).
220. Mastroeni, P. et al. Interleukin 18 contributes to host resistance and γ-interferon production in mice infected with virulent Salmonella typhimurium. Infect. Immun. 67, 478-483 (1999).
221. Flynn, J. L. et al. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254 (1993).
222. Cooper, A. M. et al. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993).
223. Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Intereukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186, 39-45 (1997).
224. Wakeham, J. et al. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guerin in IL-12-deficient mice. J. Immunol. 160, 6101-6111 (1998).
225. Newport, M. J. et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941-1949 (1996).
226. Jouanguy, E. et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335, 1956-1961 (1996).
227. Dorman, S. E. & Holland, S. M. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J. Clin. Invest 101, 2364-2369 (1998).
228. Yamada, H., Mizumo, S., Horai, R., Iwakura, Y. & Sugawara, I. Protective role of interleukin-1 in mycobacterial infection in IL-1α/β double-knockout mice. Lab. Invest. 80, 759-767 (2000).
229. Sugawara, I. et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect. Immun. 67, 2585-2589 (1999).
230. Mitsos, L. M. et al. Susceptibility to tuberculosis: a locus on mouse chromosome 19 (Trl-4) regulates Mycobacterium tuberculosis replication in the lungs. Proc. Natl Acad. Sci. USA 100, 6610-6615 (2003).
231. Tanaka, T. et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxil by macrophages. Cell 80, 353-361 (1995).
232. Everest, P., Roberts, M. & Dougan, G. Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor-α p55 receptor. Infect. Immun. 66, 3355-3364 (1998).
233. + TCR-αβ cells and IFN-γ in bacterial clearance independent of intracellular location. J. Immunol. 156, 3321-3326 (1996).
234. Jack, R. S. et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 389, 742-745 (1997).
235. Vazquez-Torres, A., Jones-Carson, J., Mastroeni, P., Ischiropoulos, H. & Fang, F. C. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages in vitro. J. Exp. Med. 192, 227-236 (2000).
236. Sawai, N. et al. Role of γ-interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect. Immun. 67, 279-285 (1999).
237. El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
238. El-Omar, E. M. The importance of interleukn-1β in Helicobacter pylori associated disease. Gut 48, 743-747 (2001).
239. El-Omar, E. M. et al. Increased risk of noncardia gastric cancer associated with pro-inflammatory cytokine gene polymorphisms. Gastroenterology 124, 1193-1201 (2003).
240. Galmiche, A. et al. The N-terminal 34-kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J. 19, 6361-6370 (2000).
241. Censini, S. et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Prac. Natl Acad. Sci. USA 93, 14648-14653 (1996).
242. Odenbreit, S. et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287, 1497-1500 (2000).
243. Segal, E. D., Cha, J., Lo, J., Falkow, S. & Tompkins, L. S. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc. Natl Acad. Sci. USA 96, 14559-14564 (1999).
244. Higashi, H. et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295, 683-686 (2002).
245. Amieva, M. R. et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300, 1430-1434 (2003).
246. Guruge, J. L. et al. Epithelial attachment afters the outcome of Helicobacter pylori infection. Proc. Natl Acad. Sci. USA 95, 3925-3930 (1998).
247. Mobley, H. L. in Helicobacter pylori: Molecular and Cellular Biology (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).
248. Josenhans, C. & Suerbaum, S. in Helicobacter pylori: Molecular and Cellular Biology (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).
249. Gerhard, M. et al. in Helicobacter pylori: Molecular and Cellular Biology (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).